The patents relate to antibodies that target calcitonin gene-related peptide, a molecule linked to migraines. Teva had argued that the antibodies were discovered after “years of ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.